ANG Lifesciences India Limited has disclosed to BSE that it does not qualify as a Large Corporate for the financial year 2025-26, making SEBI's borrowing requirements non-applicable to the company. The disclosure was made through a formal communication dated April 17, 2026, signed by Managing Director Rajesh Gupta.

Regulatory Compliance Status

The company's disclosure references several key regulatory circulars that govern Large Corporate borrowing requirements:

These circulars specifically address fund raising through issuance of debt securities by Large Corporates and the associated disclosure compliance requirements.

Annual Disclosure Exemption

Since ANG Lifesciences does not fall under the Large Corporate category for FY26, the company is exempt from filing the Annual Disclosure mentioned in Annexure B1 of the relevant SEBI circular. This exemption applies specifically to the financial year 2025-26 disclosure requirements.

Future Compliance Commitment

The company has provided assurance regarding future compliance obligations. Management stated that if ANG Lifesciences meets the Large Corporate criteria in future periods, it will:

• Inform BSE of the change in status
• Fulfill all applicable requirements for Large Corporates
• Ensure complete compliance with relevant regulations

Company Details

The disclosure was submitted under the company's CIN number L24230PB2006PLC030341 and GST number 02AAHCA5390H2ZT. The communication was addressed to the Department of Corporate Services at BSE Limited, referencing the company's script code 540694.

This regulatory disclosure ensures transparency regarding the company's compliance status and demonstrates proactive communication with market regulators regarding applicable borrowing requirements.

ANG Lifesciences India Limited has submitted its quarterly compliance certificate to BSE Limited, fulfilling regulatory requirements under SEBI (Depositories & Participants) Regulations, 2018. The pharmaceutical company, trading under BSE Security Code 540694, completed this mandatory filing for the quarter ended March 31, 2026.

Regulatory Compliance Certificate Details

The compliance certificate was issued under Regulation 74(5) of SEBI (Depositories & Participants) Regulations, 2018, covering the quarter ended March 31, 2026. Managing Director Rajesh Gupta (DIN: 01423407) submitted the certificate to BSE Limited on April 15, 2026, through reference number ANh/26-27/225.

Registrar Confirmation

Bigshare Services Private Limited, serving as the company's Registrar and Share Transfer Agent (RTA), issued the confirmation certificate on April 10, 2026. The RTA confirmed compliance with dematerialization requirements and proper handling of securities received from depository participants.

The certificate confirms that:

• Securities received from depository participants for dematerialization up to March 31, 2026 were properly confirmed to depositories
• All securities have been listed on stock exchanges where earlier issued securities are listed
• Security certificates received for dematerialization have been mutilated and cancelled after due verification
• Depository names have been substituted in the register of members as registered owners within 15 days of receipt

Corporate Information

ANG Lifesciences India Limited operates under CIN L24230PB2006PLC030341 and GST number 02AAHCA5390H2ZT. The company is headquartered at SCO-113 Darbara Complex, B-Block Rabjit Avenue, Amritsar-143001. This quarterly submission demonstrates the company's commitment to maintaining regulatory compliance and transparency in its depository operations.

The submission of this certificate ensures ANG Lifesciences remains compliant with SEBI regulations governing depositories and participants, maintaining its good standing with regulatory authorities and stock exchange requirements.